Lista de obras - Schlomo Staszewski - Dominio Público Uruguay

A 6-base pair insertion in the protease gene of HIV type 1 detected in a protease inhibitor-naive patient is not associated with indinavir treatment failure

artículo científico publicado en 2003

A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy ⬇️

artículo científico publicado en 2006

An open-label assessment of TMC 125--a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance

artículo científico publicado en 2003

Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor-susceptible human immunodeficiency virus type 1

artículo científico publicado en 2007

Changes Over Time in Risk of Initial Virological Failure of Combination Antiretroviral Therapy

article

Chronic renal failure among HIV-1-infected patients

artículo científico publicado en 2007

Comparing QuantiFERON-tuberculosis gold, T-SPOT tuberculosis and tuberculin skin test in HIV-infected individuals from a low prevalence tuberculosis country

artículo científico publicado en 2008

Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.

artículo científico publicado en 2008

Comparison of nine resistance interpretation systems for HIV-1 genotyping.

artículo científico publicado en 2003

Comprehensive Analysis of Frequency and Phenotype of T Regulatory Cells in HIV Infection: CD39 Expression of FoxP3+T Regulatory Cells Correlates with Progressive Disease ⬇️

artículo científico publicado el 3 de noviembre de 2010

Correlation of phenotypic zidovudine resistance with mutational patterns in the reverse transcriptase of human immunodeficiency virus type 1: interpretation of established mutations and characterization of new polymorphisms at codons 208, 211, and 2

artículo científico publicado en 2003

Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen

artículo científico publicado en 2008

Definition of loss of virological response in trials of antiretroviral drugs

article

Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.

artículo científico publicado en 2008

Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?

artículo científico publicado en 2008

Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression

artículo científico publicado en 2009

Effect of recombinant human growth hormone on exercise capacity in patients with HIV-associated wasting on HAART.

artículo científico publicado en 2005

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

artículo científico publicado en 2004

Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection

artículo científico publicado en 2008

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.

artículo científico publicado en 2005

Evaluation of the LiPA HIV-1 RT assay version 1: comparison of sequence and hybridization based genotyping systems

article

Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen

article

Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452)

article

HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis

artículo científico publicado en 2006

Haemolytic anaemia after nucleotide antiretroviral treatment discontinuation in a chronic hepatitis B-virus co-infected AIDS patient

artículo científico publicado en 2004

Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression

artículo científico publicado en 2002

Impact of coinfection with HIV-1 and GB virus C in patients receiving a ritonavir-boosted HAART regimen: a substudy to the MaxCmin1 trial

artículo científico publicado en 2005

Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus

artículo científico publicado en 2005

Incidence of Tuberculosis among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy in Europe and North America

artículo científico publicado en 2005

Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy

article

Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study

artículo científico publicado en 2005

M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine

artículo científico publicado en 2002

Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma

artículo científico publicado en 2007

New drugs for HIV therapy

artículo científico publicado en 2002

Patient Acceptance of Self-Injected Enfuvirtide at 8 and 24 Weeks ⬇️

artículo científico publicado el 1 de septiembre de 2003

Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings

artículo científico publicado en 2006

Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen

artículo científico publicado en 2007

Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy

artículo científico publicado en 2008

Platelet-leucocyte adhesion markers before and after the initiation of antiretroviral therapy with HIV protease inhibitors

artículo científico publicado en 2008

Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients.

artículo científico

Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count?300 cells/?L who were assigned to 7.5 MIU interleukin-2

article

Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes

artículo científico publicado en 2004

Prevalence- and gender-specific immune response to opportunistic infections in HIV-infected patients in Lesotho

artículo científico publicado en 2010

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies

artículo científico publicado en 2002

Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only?

artículo científico

Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.

artículo científico publicado en 2007

Resistance Profiles in Patients with Viral Rebound on Potent Antiretroviral Therapy

artículo científico publicado en 2000

Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen

artículo científico publicado en 2005

Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts.

artículo científico publicado en 2007

Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir

artículo científico publicado en 2004

Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis

artículo científico publicado en 2005

Short communication: Different mutation patterns in subtype CRF06_cpx after mother-to-child transmission

artículo científico publicado en 2008

Switching from a toxicity-causing antiretroviral to enfuvirtide in patients with HIV: the SWITCH TOX study

artículo científico publicado en 2008

Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults

scientific article published on 31 July 2007

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

artículo científico publicado en 2006

The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy

artículo científico publicado en 2006

The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors

artículo científico publicado en 2007

The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study

artículo científico publicado en 2008

The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors

artículo científico publicado en 2008

Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy

artículo científico publicado en 2005

Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies

artículo científico publicado en 2009

Treatment interruption in advanced failing patients

artículo científico publicado en 2007

Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years

artículo científico publicado en 2010

Use of Viral Load Measured After 4 Weeks of Highly Active Antiretroviral Therapy to Predict Virologic Outcome at 24 Weeks for HIV-1???Positive Individuals

article

Use of bioelectrical impedance analysis to determine body composition changes in HIV-associated wasting

artículo científico publicado en 2005

Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal

artículo científico publicado en 2009

[No obvious difference in Streptococcus pneumoniae antibiotic resistance profiles--isolates from HIV-positive and HIV-negative patients]

artículo científico publicado en 2008

Lista de obras de Schlomo Staszewski

A 6-base pair insertion in the protease gene of HIV type 1 detected in a protease inhibitor-naive patient is not associated with indinavir treatment failure

A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy ⬇️

An open-label assessment of TMC 125--a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance

Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor-susceptible human immunodeficiency virus type 1

Changes Over Time in Risk of Initial Virological Failure of Combination Antiretroviral Therapy

Chronic renal failure among HIV-1-infected patients

Comparing QuantiFERON-tuberculosis gold, T-SPOT tuberculosis and tuberculin skin test in HIV-infected individuals from a low prevalence tuberculosis country

Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.

Comparison of nine resistance interpretation systems for HIV-1 genotyping.

Comprehensive Analysis of Frequency and Phenotype of T Regulatory Cells in HIV Infection: CD39 Expression of FoxP3+T Regulatory Cells Correlates with Progressive Disease ⬇️

Correlation of phenotypic zidovudine resistance with mutational patterns in the reverse transcriptase of human immunodeficiency virus type 1: interpretation of established mutations and characterization of new polymorphisms at codons 208, 211, and 2

Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen

Definition of loss of virological response in trials of antiretroviral drugs

Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.

Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?

Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression

Effect of recombinant human growth hormone on exercise capacity in patients with HIV-associated wasting on HAART.

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.

Evaluation of the LiPA HIV-1 RT assay version 1: comparison of sequence and hybridization based genotyping systems

Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen

Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452)

HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis

Haemolytic anaemia after nucleotide antiretroviral treatment discontinuation in a chronic hepatitis B-virus co-infected AIDS patient

Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression

Impact of coinfection with HIV-1 and GB virus C in patients receiving a ritonavir-boosted HAART regimen: a substudy to the MaxCmin1 trial

Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus

Incidence of Tuberculosis among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy in Europe and North America

Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy

Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study

M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine

Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma

New drugs for HIV therapy

Patient Acceptance of Self-Injected Enfuvirtide at 8 and 24 Weeks ⬇️

Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings

Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen

Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy

Platelet-leucocyte adhesion markers before and after the initiation of antiretroviral therapy with HIV protease inhibitors

Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients.

Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count?300 cells/?L who were assigned to 7.5 MIU interleukin-2

Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes

Prevalence- and gender-specific immune response to opportunistic infections in HIV-infected patients in Lesotho

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies

Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only?

Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.

Resistance Profiles in Patients with Viral Rebound on Potent Antiretroviral Therapy

Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen

Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts.

Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir

Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis

Short communication: Different mutation patterns in subtype CRF06_cpx after mother-to-child transmission

Switching from a toxicity-causing antiretroviral to enfuvirtide in patients with HIV: the SWITCH TOX study

Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy

The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors

The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study

The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors

Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy

Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies

Treatment interruption in advanced failing patients

Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years

Use of Viral Load Measured After 4 Weeks of Highly Active Antiretroviral Therapy to Predict Virologic Outcome at 24 Weeks for HIV-1???Positive Individuals

Use of bioelectrical impedance analysis to determine body composition changes in HIV-associated wasting

Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal

[No obvious difference in Streptococcus pneumoniae antibiotic resistance profiles--isolates from HIV-positive and HIV-negative patients]